Exalenz Bioscience


Therapeutic Area(s):
Gastrointestinal, General Health, Primary Care, Lab Equipment
Company Status:
Revenue Growth

Company at a Glance

Exalenz Bioscience creates cutting-edge diagnostic and monitoring platforms, which analyze minute changes in a patient’s exhaled breath. Specializing in noninvasive H. pylori and liver function diagnostics, our patented BreathID® technology delivers immediate results with industry leading specificity and sensitivity.

The BreathID platform offers a user-friendly interface and a cost-effective clinical diagnostic solution that can be used in any clinical setting, including office-based practices, hospitals, laboratories and the ICU.

Technology & Product(s)

The BreathID® technology platform answers the long-standing need for fast, convenient and accurate monitoring of functional diseases of the liver and gastrointestinal tract.

BreathID products are designed for ease of use and user-friendly operation. Testing can be performed in the clinic, hospital or in the lab.

The BreathID® Hp and BreathID® Lab are the most innovative next generation Urea Breath Test (UBT) for diagnosing H. pylori infection and for post-treatment monitoring of H. pylori infection. Their technology is based on measuring the parts-per-million changes in the molecular 13C/12C ratio of the patient’s exhaled breath. This is measured before and after the ingestion of a low dosage of 13C labeled urea dissolved in water. The test is non-radioactive and completely safe. Within 10-15 minutes the real-time analysis is complete and results are available immediately. These results can easily be uploaded into the patient’s EMR.

Goals

Objectives: Locate local distributors.
Target businesses: Clinics, Hospitals and Labs.
Target Countries: Europe and Latin America.